Another year, another $9M in BARDA funding for MediWound; After PhIII results, Scynexis will submit NDA for oral yeast infection drug
The Israeli biopharma MediWound has landed $9 million in BARDA funding to support the BLA resubmission for NexoBrid with the FDA.
NexoBrid is a topically-applied drug that removes eschar in four hours without harming healthy tissues surrounding a severe burn.
MediWound received $168 million in BARDA funding back in 2015 to support development and manufacturing, and build up preparedness for mass casualty events in the US, the company said. The company landed another $16.5 million in 2020 to develop NexoBrid further. BARDA and MediWound have another contract that supports the development of NexoBrid as a chemical burn treatment.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.